the efficacy and safety of bromocriptine mesylate ( 5 to 7.5 mg per day for up to 24 weeks ) were studied in 22 clinical trials involving 226 patients who had amenorrhea/galactorrhea associated with hyperprolactinemia and no demonstrable pituitary tumor .
C0546852
bromocriptine mesylate
C0020514
hyperprolactinemia